Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation

December 6, 2018 updated by: University of Aarhus

Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation. A Randomized Cross Over Study.

A randomised trial testing the effect of percutaneous nerve evaluation and transanal irrigation on bowel function in patients after low anterior resection for rectal cancer.

Study Overview

Status

Terminated

Conditions

Detailed Description

Patients will undergo anal physiological assessment and will then be randomized to either treatment arm. The first 12 weeks they will be optimized in the conservative treatment of their bowel function before beginning active treatment with TAI or PNE. After 8 and 4 weeks respectively, the treatment will stop and they will have a period of 4 weeks back on optimized conservative treatment before beginning active treatment in the other active arm.

Detailed records of bowel, micturition and sexual function and QoL will be obtained at regular intervals during the entire trial fase.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus, Denmark, 8000
        • Colorectal Surgical Department P, Aarhus University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Low anterior resection for rectal cancer between May 2001 and May 2011

Exclusion Criteria:

  • Non-radical resection
  • metastatic disease
  • Chemotherapy
  • Radiotherapy
  • Previously treated for another cancer
  • Dementia or other mental retardation/severe mental disease
  • Inability to read and understand the Danish language
  • Recurrent disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: PNE first
patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Other Names:
  • The Peristeen Anal Irrigation System
  • Medtronic nerve stimulators
Active Comparator: TAI first
Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Other Names:
  • The Peristeen Anal Irrigation System
  • Medtronic nerve stimulators

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
changes in LARS score
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
A symptom score ranging from 0 to 42 points calculated on the basis of bowel function
baseline, 12, 16, 20, 24 and 28 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sexual function
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
self-reported sexual function measured by validated questionnaires
baseline, 12, 16, 20, 24 and 28 weeks
Bladder function
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
self-reported bladder function by validated questionnaires
baseline, 12, 16, 20, 24 and 28 weeks
Incontinence
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
faecal incontinence measured by wexner score and St. Marks incontinence score
baseline, 12, 16, 20, 24 and 28 weeks
Patient Satisfaction
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
patient satisfaction measured on a VAS
baseline, 12, 16, 20, 24 and 28 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Katrine J. Emmertsen, MD, University of Aarhus

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2011

Primary Completion (Actual)

February 1, 2018

Study Completion (Actual)

September 1, 2018

Study Registration Dates

First Submitted

January 7, 2011

First Submitted That Met QC Criteria

March 9, 2011

First Posted (Estimate)

March 11, 2011

Study Record Updates

Last Update Posted (Actual)

December 7, 2018

Last Update Submitted That Met QC Criteria

December 6, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LARS 001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rectal Cancer

Clinical Trials on Percutaneous nerve evaluation

Subscribe